22:47 , Jan 5, 2018 |  BC Week In Review  |  Company News

Angiochem grants Xinogen Chinese rights to ANG1005

Angiochem Inc. (Montreal, Quebec) granted Xinogen Hong Kong Pharma Co. Ltd. exclusive, Chinese rights to develop and commercialize ANG1005 to treat leptomeningeal carcinomatosis and brain metastases arising from metastatic breast cancer. The therapy is a...
12:08 , Jan 3, 2018 |  BC Extra  |  Company News

Angiochem, Xinogen in China deal

Angiochem Inc. (Montreal, Quebec) granted an exclusive license in China to Xinogen Hong Kong Pharma Co. Ltd. to develop and commercialize ANG1005 to treat leptomeningeal carcinomatosis and brain metastases arising from metastatic breast cancer. The...
17:54 , Jul 26, 2017 |  BC Innovations  |  Emerging Company Profile

Breaching the gates

Junction Therapeutics Ltd. ’s siRNA-based technology creates transient openings in the blood-brain barrier by targeting tight junction proteins, allowing molecules to move in and out of the brain by diffusion. The approach enhances entry of...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

ANG1005: Interim Phase II data

Interim data from 21 heavily pre-treated breast cancer patients with leptomeningeal carcinomatosis in an open-label, U.S. Phase II trial showed that ANG1005 led to 5 partial responses and 11 cases of stable disease as best...
08:00 , Jan 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2; neu)

Cancer INDICATION: Brain cancer Mouse and cell culture studies suggest ANG4043 , a conjugate of the brain-penetrant peptide angiopep-2 and an anti- HER2 mAb, could help treat brain cancer. In mice with HER2-positive brain tumors,...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Clinical News

Angiochem preclinical data

In mice bearing intracranial HER2-positive tumors, twice-weekly 15 mg/kg IV ANG4043 significantly improved median overall survival (OS) vs. vehicle-treated controls (80 vs. 45 days, p=0.0003). Data were published in Molecular Cancer Therapeutics. ANG4043 consists of...
07:00 , Jun 16, 2014 |  BioCentury  |  Regulation

Signal crossing

FDA 's workshop on neurological symptoms in inborn errors of metabolism revealed conflicts between how caregivers would like symptoms assessed and what drug companies need to test to get therapies approved. The June 10 workshop...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

ANG1005: Phase II started

Angiochem began an open-label, U.S. Phase II trial to evaluate ANG1005 in up to 40 patients with progressive or recurrent HER2-positive breast cancer with brain metastases. Late last month, FDA granted Orphan Drug and Fast...
07:00 , Mar 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Neurotensin (NTS) In vitro and rodent studies suggest a conjugate of NTS and the brain-penetrating peptide Angiopep could help treat pain. In a mouse...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

Angiochem preclinical data

In rat models of neuropathic and bone cancer pain, 0.05 mg/kg ANG2002 significantly reduced pain behaviors vs. vehicle-treated controls. Angiochem said ANG2002's analgesic efficacy was similar to that of morphine in a tail flick pain...